THE ROLE OF THALIDOMIDE ON CACHEXIA DURING

Abstract

We investigated the effect of thalidomide on cachexia and TNF-? serum levels during experimental skin carcinogenesis in mice. Female mice were divided into four groups: 1) DMBA (dissolved in acetone) induced tumorigenesis; 2) DMBA and Thalidomide (dissolved in DMSO); 3) DMBA and DMSO; and 4) Acetone. Body weight was measured once a week. Euthanasia was performed 14 weeks later, when blood was collected for the dosage of TNF-? serum levels. Mice with DMBA induced tumorigenesis had a significant loss of body weight when compared to acetone treated animals, starting at the third week and lasting the whole experiment. But there was no difference among Thalidomide treated and the others DMBA control animals, regarding body weight. High TNF-? serum levels were associated with the development of cachexia in mice during the process of experimental skin tumorigenesis. However, there was not a significant difference in the TNF-? serum levels when compared control mice and thalidomide treated mice. These results suggest that thalidomide does not interfere with skin tumorigenesis, cachexia and serum TNF-? levels in Balb/C mice. In addition, high TNF-? serum levels are associated to weight loss during experimental carcinogenesis.